- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
Daniel F. Hayes, MD
Clinical Director, Breast Oncology Program
Stuart B. Padnos Professor of Breast Cancer Research
University of Michigan
Ann Arbor, Michigan
- Seeking to identify and validate clinical biomarkers to inform patient care and the design of future clinical trials.
- Ongoing efforts include the collection and analysis of clinical samples to identify clinical biomarkers.
- These efforts are leading to biomarkers that can inform patient care.
Clinical trials are crucial to advancements in the management of breast cancer. They also provide a rich resource of de-identified patient samples acquired by patient consent during the course of a trial. These samples can be used for studies to identify biomarkers to predict how patients will respond to a particular therapy–the basis of precision medicine. Dr. Hayes is leading efforts by one of the major national cooperative groups to conduct these kinds of studies.
Full Research Summary
The North American Breast Cancer Group (NABCG) and the Breast International Group (BIG) have prospectively collected and stored breast cancer tissues, blood, serum, and DNA from patients who participated in clinical trials to conduct correlative science studies of new or promising tumor biomarkers.
Since 2006, BCRF has supplied support for ongoing correlative science activities of the NABCG and BIG, including support for approved studies, for infrastructure projects related to archived specimens, and collaborations between the two groups.
The archived tissues, which have been evaluated for the major breast cancer biomarkers, estrogen receptor, progesterone receptor and HER2, are publicly available to others in the research community.
Major workshops have led to initiatives within the NABCG for pharmacogenomics studies, standardization of assays for an important biomarker, Ki67, and correlative studies for major clinical trials.
In the coming year, the NABCG will continue to provide support for important correlative and translational studies, as well as ongoing efforts by the various cooperative clinical trial groups to build new tissue platforms for analysis of tumor specimen and perform routine marker analyses from clinical trial specimens
These studies are validating biomarkers that may change prognosis or predict whether a patient will or will not benefit from a particular therapy, or even predict side effects. The information resulting from these efforts can inform clinical care for patients with breast cancer or the design of future trials in which the respective marker is used to make the clinical investigations more efficient and clinically relevant.
Daniel Hayes, MD, is the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center (UMCCC) and the Stuart B. Padnos Professor of Breast Cancer Research. He received AB (1974) and MS (1977) degrees at Indiana University, his MD from the Indiana University School of Medicine (1979), a residency in Internal Medicine at the UTHSC, Dallas, Texas (Parkland Memorial Hospital, 1979-1982), and a fellowship in Medical Oncology at Harvard’s Dana Farber Cancer Institute (DFCI, 1982–1985). From 1992–1996, he was Medical Director of the Breast Evaluation Center at DFCI. In 1996, he moved to the Georgetown University Lombardi Cancer Center, and he joined the UMCCC in 2001. Dr. Hayes has a national and international reputation in the field of experimental therapeutics targeted to breast cancer, working on serum and tissue markers such as HER-2, circulating tumor cells and pharmacogenomics which have prognostic and/or predictive value in the treatment of breast cancer. In June 2015 he became president-elect of the American Society of Clinical Oncology.